NEWS

Jan 09, 2020

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology
Acepodia Logo

Acepodia Taiwan

Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd., Sijhih Dist., 

New Taipei City 22175, 

Taiwan (R.O.C.)

 

Acepodia USA

Burlingame, California USA

Tel:  +886-2-26976100 
info@acepodiabio.com

© 2018 Acepodia Inc.

All rights reserved